These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 7903906)

  • 41. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
    Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
    Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.
    Dunphy FR; Spitzer G; Buzdar AU; Hortobagyi GN; Horwitz LJ; Yau JC; Spinolo JA; Jagannath S; Holmes F; Wallerstein RO
    J Clin Oncol; 1990 Jul; 8(7):1207-16. PubMed ID: 2358837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
    Meisenberg BR; Miller WE; McMillan R
    Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
    Vaughan WP; Kris E; Vose J; Bierman PJ; Gwilt P; Armitage JO
    J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
    Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
    Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.
    Ghalie R; Richman CM; Adler SS; Cobleigh MA; Korenblit AD; Manson SD; McLeod BC; Taylor SG; Valentino LA; Wolter J
    J Clin Oncol; 1994 Feb; 12(2):342-6. PubMed ID: 8113841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent.
    Vaughan WP; Bierman PJ; Reed EC; Glenn LD; Kessinger A; Armitage JO
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):110-5. PubMed ID: 1641652
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
    De Rosa L; Anghel G; Pandolfi A; Riccardi M; Amodeo R; Majolino I
    Int J Hematol; 2004 Jan; 79(1):85-91. PubMed ID: 14979484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
    Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support.
    Dunphy FR; Spitzer G; Fornoff JE; Yau JC; Huan SD; Dicke KA; Buzdar AU; Hortobagyi GN
    Cancer; 1994 Apr; 73(8):2157-67. PubMed ID: 8156520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
    Somlo G; Doroshow JH; Forman SJ; Odom-Maryon T; Lee J; Chow W; Hamasaki V; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Simpson J; Molina A
    J Clin Oncol; 1997 Aug; 15(8):2882-93. PubMed ID: 9256132
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP).
    Ballestrero A; Ferrando F; Stura P; Puglisi M; Brema F; Patrone F
    Am J Clin Oncol; 1997 Jun; 20(3):266-71. PubMed ID: 9167751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.